"{\"header\":{\"key\":\"MainHeader\",\"orderOnPage\":-1,\"model\":{\"rootOrganizationType\":\"ysm\",\"rootOrganizationLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/\",\"text\":\"Yale School of Medicine\"},\"navigationItems\":[{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/\",\"text\":\"About YSM\"},\"subNavigationItems\":[{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/\",\"text\":\"Office of the Dean\"},\"subNavigationItems\":[{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/committees/\",\"text\":\"Committees\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/committees/appointments_promotions/\",\"text\":\"Appointments & Promotions Committees\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/committees/adhoc/\",\"text\":\"Ad Hoc Committees\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/committees/searches/\",\"text\":\"Current Searches\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/fac/\",\"text\":\"Faculty Advisory Council\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/fac/documents/\",\"text\":\"FAC Documents\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/workshop/\",\"text\":\"Dean's Workshop\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/workshop/past/\",\"text\":\"Past Workshops\"}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/deanoffice/state-of-the-school/\",\"text\":\"State of the School\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/findpeople/\",\"text\":\"Find People\"},\"subNavigationItems\":[{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/findpeople/leadership/\",\"text\":\"YSM Leadership & Administration\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/findpeople/leadership/charts/\",\"text\":\"Organization Charts\"}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/findpeople/facultylist/\",\"text\":\"A-Z Faculty List\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/findpeople/stafflist/\",\"text\":\"A-Z Staff List\"}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/departments/\",\"text\":\"Departments & Sections\"},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/resources/\",\"text\":\"Resources & Support\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/resources/sha/\",\"text\":\"Sexual Misconduct Resources\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/community/\",\"text\":\"Community & World\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/community/facultymap/\",\"text\":\"Faculty Global Map\"}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/about/giving/\",\"text\":\"Giving\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/edu/\",\"text\":\"Education\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/edu/md/\",\"text\":\"Medical Degree Programs\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/edu/pa/\",\"text\":\"PA Programs\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/edu/publichealth/\",\"text\":\"Public Health Programs\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/edu/otherphd/\",\"text\":\"Other PhD Programs\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/research/\",\"text\":\"Research\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/research/researchbydept/\",\"text\":\"Research by Department\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/research/services/\",\"text\":\"Research Services\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/research/faculty-by-keyword/\",\"text\":\"Faculty by Research Keyword\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/research/search-by-keyword/\",\"text\":\"Search for Faculty by Research Keyword\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"https://covid.yale.edu/research/reopening/\",\"text\":\"Re-opening Research Facilities Information\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"https://covid.yale.edu/news-article/24013/\",\"text\":\"Covid-19 Human Subjects Research Guidance\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/research/escro/\",\"text\":\"Embryonic Stem Cell Research Oversight\"}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"https://www.yalemedicine.org\",\"text\":\"Patient Care\"},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/\",\"text\":\"Diversity\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/support/\",\"text\":\"Support & Resources\"},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/antiracism/\",\"text\":\"Anti-Racism Resources\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/antiracism/contacts/\",\"text\":\"Contacts\"}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/community/\",\"text\":\"Community Building\"},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/paps/\",\"text\":\"Program for Art in Public Spaces\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/paps/execcomm/\",\"text\":\"Executive Committee\"},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/paps/exhibits/\",\"text\":\"Exhibits\"},\"subNavigationItems\":[{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/paps/exhibits/aperture/\",\"text\":\"Aperture\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/paps/exhibits/aperture/gallery/\",\"text\":\"Gallery\"}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/paps/exhibits/selfreflection/\",\"text\":\"Self-Reflection\"}],\"hasCurrentLink\":false}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/training/\",\"text\":\"Training\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/news/\",\"text\":\"News\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/contact/\",\"text\":\"Contact\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/diversity/galleries/\",\"text\":\"Photo Galleries\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/news/\",\"text\":\"News\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/news/beyond-sterling-hall/\",\"text\":\"Beyond Sterling Hall\"},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/news/yale-medicine-magazine/\",\"text\":\"Yale Medicine Magazine\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/news/yale-medicine-magazine/print-version/\",\"text\":\"Print Magazine PDFs\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/news/medicineatyale/\",\"text\":\"Medicine@Yale\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/news/medicineatyale/print-version/\",\"text\":\"Print Newsletter PDFs\"}],\"hasCurrentLink\":false},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/news/ysm-events/\",\"text\":\"YSM Events Newsletter\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/news/social/\",\"text\":\"Social Media\"}],\"hasCurrentLink\":false},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/\",\"text\":\"A-Z Index\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/academicdepartments/\",\"text\":\"Academic Departments\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/phonenumbers/\",\"text\":\"Phone Numbers\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/abbreviations/\",\"text\":\"Abbreviations\"},{\"topLink\":{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/\",\"text\":\"Gateways\"},\"subNavigationItems\":[{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/alumni/\",\"text\":\"Alumni & Friends Gateway\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/current-students/\",\"text\":\"Current Students & Trainees Gateway\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/faculty-staff/\",\"text\":\"Faculty & Staff Gateway\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/postdocs/\",\"text\":\"Postdoctoral Gateway\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/training/\",\"text\":\"Professional, Residency, and Fellowship Training\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/prospective-students/\",\"text\":\"Prospective Students Gateway\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/research-orgs/\",\"text\":\"Research Programs, Centers, & Organizations\"},{\"isCurrentLink\":false,\"rootOrganizationPrefix\":null,\"url\":\"/ysm/departments/gateways/researchers/\",\"text\":\"Researchers Gateway\"}],\"hasCurrentLink\":false}],\"hasCurrentLink\":false}],\"browseLinks\":[{\"url\":\"https://medicine.yale.edu/departments/gateways/prospective-students/\",\"text\":\"Prospective Students\"},{\"url\":\"https://medicine.yale.edu/departments/gateways/current-students/\",\"text\":\"Current Students & Trainees\"},{\"url\":\"https://medicine.yale.edu/departments/gateways/faculty-staff/\",\"text\":\"Faculty & Staff\"},{\"url\":\"https://medicine.yale.edu/departments/gateways/training/\",\"text\":\"Residents & Fellows\"},{\"url\":\"https://medicine.yale.edu/departments/gateways/researchers/\",\"text\":\"Researchers\"},{\"url\":\"https://medicine.yale.edu/departments/gateways/postdocs/\",\"text\":\"Postdocs\"},{\"url\":\"https://medicine.yale.edu/departments/gateways/alumni/\",\"text\":\"Alumni & Friends\"},{\"url\":\"https://medicine.yale.edu/departments/gateways/visitors/\",\"text\":\"Other Visitors\"}],\"popularLinks\":{\"title\":\"Find Information On\",\"items\":[{\"title\":\"Housing\",\"items\":[{\"title\":\"Yale Listings\",\"items\":[{\"url\":\"https://housing.yale.edu/graduate-housing/es-harkness-hall\",\"text\":\"YSM Harkness Dormitory\"},{\"url\":\"https://housing.yale.edu/graduate-housing\",\"text\":\"Graduate Housing\"}],\"columnsCount\":1},{\"title\":\"Other Long-Term\",\"items\":[{\"url\":\"http://www.cawhite.com/apartments.html\",\"text\":\"Apartments, CA White New Haven\"},{\"url\":\"http://newhaven.craigslist.org/\",\"text\":\"New Haven CraigsList\"}],\"columnsCount\":1},{\"title\":\"Short-Term\",\"items\":[{\"url\":\"http://www.yale.edu/visitor/lodging.html\",\"text\":\"Hotels Within Walking Distance\"},{\"url\":\"http://www.infonewhaven.com/content/staying-here-hotels\",\"text\":\"Hotels, Info New Haven\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Dining\",\"items\":[{\"title\":\"On YSM Campus\",\"items\":[{\"url\":\"http://www.yaledining.org/menu.cfm?mDH=169\",\"text\":\"Café Med\"},{\"url\":\"http://www.nytimes.com/2010/04/25/nyregion/25dinect.html\",\"text\":\"Carts Outside 333 Cedar Street\"},{\"url\":\"http://www.yale.edu/dining/\",\"text\":\"Dining Services, Yale\"}],\"columnsCount\":1},{\"title\":\"Eat out\",\"items\":[{\"url\":\"http://www.newhavenadvocate.com/dining/blog-5.html\",\"text\":\"Advocate\"},{\"url\":\"http://www.aubonpain.com/\",\"text\":\"Au Bon Pain\"},{\"url\":\"http://www.cafegeorgebypaula.com/\",\"text\":\"Cafe George by Paula\"},{\"url\":\"http://www.gourmetheaven.com/\",\"text\":\"Gourmet Heaven\"},{\"url\":\"http://www.rexdevelopment.org/visitor-information.html\",\"text\":\"Greater New Haven\"},{\"url\":\"http://www.infonewhaven.com/dining\",\"text\":\"Info New Haven\"},{\"url\":\"http://medstation.yale.edu/dining/\",\"text\":\"Student Suggestions\"},{\"url\":\"http://www.templegrill.com/\",\"text\":\"Temple Grill\"},{\"url\":\"http://www.yelp.com/search?find_desc=&action_search.x=0&action_search.y=0&action_search=Search&ns=1&rpp=10&find_loc=333+Cedar+St%2CNew+Haven%2CCT\",\"text\":\"Yelp.com\"},{\"url\":\"http://www.yorksidepizza.com/\",\"text\":\"Yorkside\"},{\"url\":\"http://zaroka.com/\",\"text\":\"Zaroka\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Travel\",\"items\":[{\"title\":\"Maps & Directions\",\"items\":[{\"url\":\"https://www.ynhh.org/locations/new-haven-20-york-street.aspx\",\"text\":\"Yale New Haven Hospital Directions & Parking\"},{\"url\":\"/maps/\",\"text\":\"YSM Maps & Directions\"}],\"columnsCount\":1},{\"title\":\"Transportation Services\",\"items\":[{\"url\":\"https://your.yale.edu/community/getting-around-yale/shuttle\",\"text\":\"Shuttle, Yale\"},{\"url\":\"https://your.yale.edu/administrative-services/travel-relocation-fleet/travel-management\",\"text\":\"Travel Management, Yale\"},{\"url\":\"https://to.yale.edu/bikeshare\",\"text\":\"Bikeshare, Yale\"},{\"url\":\"https://visitorcenter.yale.edu/\",\"text\":\"Visitor Center, Yale\"}],\"columnsCount\":1},{\"title\":\"International Travel\",\"items\":[{\"url\":\"http://world-toolkit.yale.edu/\",\"text\":\"International Toolkit—Yale & the World\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Parking\",\"items\":[{\"title\":\"Yale\",\"items\":[{\"url\":\"https://your.yale.edu/community/getting-around-yale/parking\",\"text\":\"Yale University Parking\"},{\"url\":\"http://www.ynhh.org/visitor-information/locations-directions.aspx\",\"text\":\"Yale New Haven Hospital Parking\"}],\"columnsCount\":1},{\"title\":\"Off-Yale\",\"items\":[{\"url\":\"https://parknewhaven.com/\",\"text\":\"Park New Haven\"},{\"url\":\"https://www.propark.com/locations/\",\"text\":\"Propark\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Computing\",\"items\":[{\"title\":\"Quick Services\",\"items\":[{\"url\":\"http://yale.edu/its\",\"text\":\"Information Technology Services (ITS)\"},{\"url\":\"https://software.yale.edu/\",\"text\":\"ITS: Software Library\"},{\"link\":{\"url\":\"https://its.yale.edu/sites/default/files/imce/pdfs/crform.pdf\",\"text\":\"ITS: Computing Request Form\"},\"type\":\"pdf\",\"text\":\"ITS: Computing Request Form\"},{\"url\":\"http://its.yale.edu/how-to/change-your-yale-passwords\",\"text\":\"Change NetID Password\"},{\"url\":\"https://its.yale.edu/services/communication-and-collaboration/document-sharing-and-team-sites/box-yale\",\"text\":\"Box at Yale (cloud-based file sharing)\"},{\"url\":\"https://its.yale.edu/services/email-and-collaboration-services/email-and-messaging/yaleconnect/office-365\",\"text\":\"Yale Connect Mail (Office 365)\"},{\"url\":\"https://its.yale.edu/webmail-portal\",\"text\":\"Webmail Portal\"}],\"columnsCount\":1},{\"title\":\"Your Phone & Computer\",\"items\":[{\"url\":\"https://yale.service-now.com/it?id=service_offering&sys_id=0b688dcd6fbb31007ee2abcf9f3ee426\",\"text\":\"ITS: Antivirus Services\"},{\"url\":\"https://its.yale.edu/software-technology/buying-guide/recommended-computing-devices\",\"text\":\"ITS: Recommended Computing Devices\"},{\"url\":\"https://cybersecurity.yale.edu/\",\"text\":\"ITS: Cybersecurity\"},{\"url\":\"https://its.yale.edu/help/it-support-providers\",\"text\":\"ITS: Support Providers\"},{\"url\":\"https://hipaa.yale.edu/security/breach-prevention/smartphones\",\"text\":\"Smartphone HIPAA Security Policy & Guidelines\"}],\"columnsCount\":1},{\"title\":\"Access & Help\",\"items\":[{\"url\":\"https://its.yale.edu/it-help-and-support\",\"text\":\"ITS: Help Desk (203-432-9000)\"},{\"url\":\"https://its.yale.edu/services/accounts-and-access/netreg-device-registration\",\"text\":\"ITS: NetReg (Device Registration)\"},{\"url\":\"https://yale.service-now.com/it?id=service_offering&sys_id=0b688dcd6fbb31007ee2abcf9f3ee426\",\"text\":\"ITS: Antivirus Services\"},{\"url\":\"https://cybersecurity.yale.edu/\",\"text\":\"ITS: Cybersecurity\"},{\"url\":\"https://its.yale.edu/services/accounts-and-access/campus-access-vpn\",\"text\":\"ITS: Off Campus Access (VPN)\"},{\"url\":\"https://its.yale.edu/services/internet-phones-and-television/network-infrastructure-services/wifi\",\"text\":\"ITS: Wifi Coverage\"},{\"url\":\"http://library.medicine.yale.edu/services/computing\",\"text\":\"Computing in the Medical Library\"}],\"columnsCount\":1},{\"title\":\"Web & Applications\",\"items\":[{\"url\":\"https://medicine.yale.edu/web\",\"text\":\"YSM Web Support & Services\"},{\"url\":\"https://medicine.yale.edu/ipc/what/identity/powerpoint.aspx\",\"text\":\"YSM PowerPoint Templates\"}],\"columnsCount\":1},{\"title\":\"Research Computing\",\"items\":[{\"url\":\"http://research.computing.yale.edu/\",\"text\":\"Yale Center for Research Computing\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Health & Safety\",\"items\":[{\"title\":\"Emergencies\",\"items\":[{\"url\":\"https://yalehealth.yale.edu/\",\"text\":\"Yale Health\"},{\"url\":\"https://yalehealth.yale.edu/directory/departments/acute-care\",\"text\":\"Yale Health: Acute Care\"},{\"url\":\"https://yalehealth.yale.edu/appointments/emergencies\",\"text\":\"Yale Health: Emergencies\"},{\"url\":\"https://emergency.yale.edu/\",\"text\":\"Yale University Emergency Management\"},{\"url\":\"https://your.yale.edu/community/public-safety\",\"text\":\"Public Safety (on campus, dial 911)\"},{\"url\":\"http://www.yale.edu/oehs/emergency_subpage.htm\",\"text\":\"Spill, Exposure, or Puncture\"},{\"url\":\"http://world-toolkit.yale.edu/travel_overview\",\"text\":\"While Traveling\"}],\"columnsCount\":1},{\"title\":\"Find a Doctor\",\"items\":[{\"url\":\"https://yalehealth.yale.edu/directory/clinicians\",\"text\":\"Yale Health Clinicians\"},{\"url\":\"https://www.ynhh.org/find-a-doctor.aspx\",\"text\":\"Yale New Haven Hospital\"},{\"url\":\"https://www.yalemedicine.org/doctors/\",\"text\":\"Yale Medicine\"}],\"columnsCount\":1},{\"title\":\"For Scientists\",\"items\":[{\"url\":\"http://www.yale.edu/oehs/\",\"text\":\"Environmental Health & Safety\"},{\"url\":\"http://rsc.med.yale.edu/login.asp?url=myApps.asp\",\"text\":\"Radiation Safety\"}],\"columnsCount\":1},{\"title\":\"Personal Safety\",\"items\":[{\"url\":\"https://your.yale.edu/community/public-safety\",\"text\":\"Public Safety (on campus, dial 911)\"},{\"url\":\"https://medicine.yale.edu/sha/\",\"text\":\"Sexual Harassment & Assault Policy and Resources\"},{\"url\":\"https://medicine.yale.edu/dean/policies/smoking.aspx\",\"text\":\"Designated Smoking Areas\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Conflict Resolution\",\"items\":[{\"url\":\"http://www.yale.edu/chaplain/\",\"text\":\"Chaplain, University\"},{\"url\":\"https://medicine.yale.edu/owm/\",\"text\":\"Office of Women in Medicine\"},{\"url\":\"https://medicine.yale.edu/ombuds/\",\"text\":\"Ombudsperson\"},{\"url\":\"http://sharecenter.yale.edu/\",\"text\":\"Sexual Harassment & Assault (SHARE)\"},{\"url\":\"https://medicine.yale.edu/sha/\",\"text\":\"Sexual Misconduct Resources @ YSM\"}],\"columnsCount\":1},{\"title\":\"Facilities\",\"items\":[{\"title\":\"\",\"items\":[{\"url\":\"http://java.facilities.yale.edu/fwr/\",\"text\":\"Facilities Work Request\"},{\"url\":\"/facilities/\",\"text\":\"YSM Facilities Planning & Construction (FACPC)\"},{\"url\":\"https://facilities.yale.edu/\",\"text\":\"Office of Facilities, Yale University\"},{\"url\":\"https://medicine.yale.edu/dean/policies/smoking.aspx\",\"text\":\"Designated Smoking Areas\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Library\",\"items\":[{\"url\":\"http://library.medicine.yale.edu/\",\"text\":\"Harvey Cushing/John Hay Whitney Medical Library\"}],\"columnsCount\":1},{\"title\":\"Courses & Academics\",\"items\":[{\"title\":\"Course Listings\",\"items\":[{\"url\":\"http://www.yale.edu/printer/bulletin/htmlfiles/med/departments-and-sections.html\",\"text\":\"By Department\"}],\"columnsCount\":1},{\"title\":\"Academic\",\"items\":[{\"url\":\"https://bluedogs.med.yale.edu/lcms/\",\"text\":\"BlueDogs\"},{\"url\":\"https://classesv2.yale.edu/\",\"text\":\"Classes V2 (Yale)\"},{\"url\":\"/education/quicklinks/academiccalendar.aspx\",\"text\":\"YSM Academic Calendar\"},{\"url\":\"http://bulletin.printer.yale.edu/htmlfiles/med/departments-and-sections.html\",\"text\":\"Course Handbook (Bulletin)\"},{\"url\":\"/edu/md.aspx\",\"text\":\"Degree Programs\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"url\":\"https://medicine.yale.edu/departments/\",\"text\":\"A-Z Index\"},{\"url\":\"https://medicine.yale.edu/departments/#page4\",\"text\":\"Administrative Departments and Sections\"},{\"title\":\"Employee Training\",\"items\":[{\"title\":\"Courses & Getting Started\",\"items\":[{\"url\":\"https://your.yale.edu/what-you-need-know-get-started-yale\",\"text\":\"Getting Started at Yale\"},{\"url\":\"https://your.yale.edu\",\"text\":\"It's Your Yale\"},{\"url\":\"https://your.yale.edu/work-yale/managers/managing-and-developing-your-team\",\"text\":\"Managing and Developing Your Team\"},{\"url\":\"https://your.yale.edu/you-start-your-new-job\",\"text\":\"New Employee Orientation\"}],\"columnsCount\":1},{\"title\":\"Training\",\"items\":[{\"url\":\"http://www.yale.edu/training/\",\"text\":\"Yale Assessment\"},{\"url\":\"http://www.yale.edu/oehs/training.htm\",\"text\":\"Environmental Health & Safety\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"News & Publications\",\"items\":[{\"title\":\"Medical\",\"items\":[{\"url\":\"https://medicine.yale.edu/news/index.aspx\",\"text\":\"School of Medicine\"},{\"url\":\"https://news.yale.edu/topics/health-medicine\",\"text\":\"YaleNews Health & Medicine Topics\"},{\"url\":\"http://communications.yale.edu/media/experts\",\"text\":\"Yale University Office of Public Affairs & Communications - Yale Medical Experts\"}],\"columnsCount\":1},{\"title\":\"Yale\",\"items\":[{\"url\":\"https://news.yale.edu/\",\"text\":\"YaleNews\"},{\"url\":\"http://www.yaledailynews.com/\",\"text\":\"Yale Daily News\"},{\"url\":\"http://www.yaleherald.com/\",\"text\":\"Yale Herald\"},{\"url\":\"http://communications.yale.edu/\",\"text\":\"Office of Public Affairs & Communications \"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Calendars & Events\",\"items\":[{\"title\":\"Calendars\",\"items\":[{\"url\":\"https://your.yale.edu/work-yale/benefits/paid-time/official-yale-holidays\",\"text\":\"Official Yale University Holidays\"},{\"url\":\"/edu/academic-calendar.aspx\",\"text\":\"YSM Academic Calendar\"},{\"url\":\"http://yalecollege.yale.edu/content/academic-calendars\",\"text\":\"Yale University Academic Calendar\"}],\"columnsCount\":1},{\"title\":\"Events\",\"items\":[{\"url\":\"https://www.ynhh.org/events.aspx\",\"text\":\"Yale New Haven Hospital Events\"},{\"url\":\"https://medicine.yale.edu/calendar.aspx\",\"text\":\"Yale School of Medicine Event Calendar\"},{\"url\":\"http://calendar.yale.edu/cal/main/showEventList.rdo\",\"text\":\"Yale Calendar of Events\"},{\"url\":\"http://calendar.cityofnewhaven.com/scripts/webevent.pl?cmd=calmonth&userid=guest&calID=44\",\"text\":\"City of New Haven\"},{\"url\":\"http://www.infonewhaven.com/events\",\"text\":\"InfoNewHaven.com\"},{\"url\":\"http://www.rexdevelopment.org\",\"text\":\"VisitNewHaven.com\"}],\"columnsCount\":1}],\"columnsCount\":1},{\"title\":\"Culture & Activities\",\"items\":[{\"title\":\"Art Museums\",\"items\":[{\"url\":\"http://www.eliwhitney.org/\",\"text\":\"Eli Whitney Museum\"},{\"url\":\"http://www.yale.edu/ycba/\",\"text\":\"Center for British Art, Yale\"},{\"url\":\"http://www.yale.edu/artgallery/\",\"text\":\"Art Gallery, Yale\"},{\"url\":\"http://www.yale.edu/art/\",\"text\":\"School of Art, Yale\"},{\"url\":\"http://www.peabody.yale.edu/\",\"text\":\"Peabody Museum of Natural History, Yale\"}],\"columnsCount\":1},{\"title\":\"Music\",\"items\":[{\"url\":\"https://newhavensymphony.org/\",\"text\":\"New Haven Symphony Orchestra\"},{\"url\":\"http://music.yale.edu/\",\"text\":\"Yale School of Music\"},{\"url\":\"https://medicine.yale.edu/orchestra/\",\"text\":\"Yale Medical Symphony Orchestra\"}],\"columnsCount\":1},{\"title\":\"Theater\",\"items\":[{\"url\":\"http://www.longwharf.org/\",\"text\":\"Long Wharf Theater\"},{\"url\":\"http://www.shubert.com/\",\"text\":\"Shubert Theater\"},{\"url\":\"http://yalecabaret.org/\",\"text\":\"Yale Cabaret\"},{\"url\":\"https://yaledramat.org/\",\"text\":\"Yale Dramatic Association\"},{\"url\":\"http://www.yale.edu/yalerep/\",\"text\":\"Yale Repertory Theater\"},{\"url\":\"http://www.yale.edu/drama/index.html\",\"text\":\"Yale School of Drama\"}],\"columnsCount\":1}],\"columnsCount\":1}],\"columnsCount\":2},\"searchUrl\":\"/ysm/search/\"}},\"footer\":{\"key\":\"Footer\",\"orderOnPage\":-1,\"model\":{\"organizationType\":\"ysm\",\"primarySections\":[{\"mailingAddresses\":[{\"id\":4944,\"officeName\":null,\"name\":null,\"addressLine1\":\"333 Cedar Street\",\"addressLine2\":null,\"city\":\"New Haven\",\"region\":\"CT\",\"country\":\"United States\",\"postalCode\":\"06510\"}],\"link\":{\"url\":\"https://medicine.yale.edu/maps/\",\"text\":\"Maps & Directions\"}},{\"title\":\"Pioneering\",\"mottoWords\":[\"Education\",\"Patient Care\",\"Research\"],\"link\":{\"url\":\"/ysm/about/giving/\",\"text\":\"Support Us\"}},{\"eventsCount\":224,\"period\":\"2020-07-09T04:00:00Z\",\"periodType\":\"month\",\"link\":{\"url\":\"https://medicine.yale.edu/calendar/\",\"text\":\"Calendar\"}},{\"socialMediaLinks\":{\"facebook\":\"https://facebook.com/YaleSchoolOfMedicine\",\"twitter\":\"https://twitter.com/yalemed\",\"instagram\":\"https://instagram.com/yaleschoolofmed\",\"linkedin\":\"https://linkedin.com/school/yale-university-school-of-medicine\"},\"link\":{\"url\":\"https://medicine.yale.edu/contact/\",\"text\":\"Contact Us\"}}],\"secondaryLinks\":[{\"url\":\"/ysm/intranet/\",\"text\":\"Intranet\"},{\"url\":\"mailto:ysm.editor@yale.edu\",\"text\":\"Site Editor\"},{\"url\":\"https://medicine.yale.edu/communications/policies/policies/accessibility/\",\"text\":\"Accessibility at YSM\"},{\"url\":\"/ysm/privacy/\",\"text\":\"Terms & Privacy Policy\"},{\"url\":\"https://yale.edu/\",\"text\":\"Yale University\"},{\"url\":\"http://directory.yale.edu/\",\"text\":\"Yale Phonebook\"},{\"url\":\"http://library.medicine.yale.edu/\",\"text\":\"Library & Reference\"}],\"poweredByLink\":{\"url\":\"https://medicine.yale.edu/communications/\",\"text\":\"Powered by Yale School of Medicine web platforms\"},\"lastModifiedDate\":\"2019-07-15T08:40:02\"}},\"pageSettings\":{\"hasContentOverlay\":false,\"hasCustomLayout\":true,\"isHomePage\":false,\"isDepartmentHeader\":false,\"showSuppressedImageWarnings\":false,\"showBugReportButton\":false,\"showAnnouncementModal\":true,\"showDownloadAsWordButton\":false,\"reCaptchaSiteKey\":\"6LdBkE0UAAAAAPaY0NU7aiTHhHfpaBRKXzTH3k73\",\"facebookShareUrl\":\"https://www.facebook.com/dialog/share?app_id=604142276782606&display=popup&href=\",\"isWordPageVersion\":false},\"googleAnalyticsSettings\":{\"ysmSitesKey\":\"UA-16886888-1\",\"websites4Key\":\"UA-148343683-1\",\"siteKey\":\"UA-63667619-1\",\"sitesGroupKey\":null,\"mediaLibraryKey\":\"UA-132905387-1\"},\"googleTagManagerContainerId\":\"GTM-T29B2V8\",\"pageMetaData\":{\"socialMediaTitle\":\"Lieping Chen, MD, PhD\",\"siteName\":\"Yale School of Medicine\",\"googleSiteVerification\":\"JoMai-V4PlMR-HzbOo7lf7bKlMd68b6HRlPZcTQUcg0\",\"keywords\":\"\",\"twitterAccountName\":\"@yalemed\",\"twitterCardType\":\"summary\",\"facebookAppId\":\"604142276782606\",\"url\":\"https://medicine.yale.edu/ysm/profile/lieping_chen/?tab=location&locationId=939\",\"resourceBaseUrl\":\"https://ysm-websites4-live-prod.azureedge.net\",\"faviconUrl\":\"/ysm/images/favicon_tcm25-529.ico\",\"iconsFolderUrl\":\"https://ysm-websites4-live-prod.azureedge.net/icons/ysm\",\"isNoIndex\":false,\"title\":\"Lieping Chen, MD, PhD < Yale School of Medicine\",\"description\":\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules\",\"imageMetaData\":{\"alt\":\"\",\"width\":1200,\"height\":630,\"url\":\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\",\"secureUrl\":\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\"},\"videoMetaData\":null,\"audioMetaData\":null,\"author\":null,\"pageType\":\"website\",\"publishDate\":\"2020-07-09T06:35:42.7059182-04:00\",\"canonicalUrl\":\"https://medicine.yale.edu/ysm/profile/lieping_chen/\"},\"popularSearches\":[\"triennial\",\"covid\",\"ibudilast\"],\"pageStructuredData\":[{\"schemaName\":\"Person\",\"jsonData\":\"{\\\"@type\\\":\\\"Person\\\",\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},\\\"name\\\":\\\"Lieping Chen\\\",\\\"description\\\":\\\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\\\",\\\"url\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"email\\\":\\\"lieping.chen@yale.edu\\\",\\\"telephone\\\":\\\"+12037371819\\\",\\\"honorificSuffix\\\":[null,\\\"MD\\\",\\\"PhD\\\"],\\\"award\\\":[\\\"Elected Academician 2018\\\",\\\"Kurt Hellman Award 2018\\\",\\\"Giants of Cancer Care 2018\\\",\\\"Warren Alpert Foundation Prize 2017\\\",\\\"AAI-Steinman Award 2016\\\",\\\"William B. Coley Award 2014\\\"],\\\"jobTitle\\\":[\\\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\\\",\\\"Co-Leader, Cancer Immunology, Yale Cancer Center\\\"],\\\"affiliation\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Cancer Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Chen Lab\\\",\\\"url\\\":\\\"https://medicine.yale.edu/lab/chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Human and Translational Immunology Program\\\",\\\"url\\\":\\\"https://medicine.yale.edu/immuno/programs/hti.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunobiology\\\",\\\"url\\\":\\\"http://immunobiology.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunology\\\",\\\"url\\\":\\\"http://bbs.yale.edu/immunology\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Internal Medicine\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org/research/education/index/about/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Medical Oncology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/medonc/index.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Office of Cooperative Research\\\",\\\"url\\\":\\\"http://ocr.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatic Diseases Research Core\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatology, Allergy, & Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/raci/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"SPORE in Lung Cancer\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Cancer Center\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\\\",\\\"url\\\":\\\"http://bbs.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale University\\\",\\\"url\\\":\\\"https://www.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"alumniOf\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Drexel University, Pathology and Laboratory Medicine (1989)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Beijing Union Medical College, Beijing, China, Immunology (1986)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Fujian Medical College (1982)\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\\\",\\\"description\\\":\\\"\\\",\\\"height\\\":1200,\\\"width\\\":630,\\\"@context\\\":\\\"http://schema.org\\\"},\\\"@context\\\":\\\"http://schema.org\\\"}\"},{\"schemaName\":\"MedicalScholarlyArticle\",\"jsonData\":\"{\\\"@type\\\":\\\"MedicalScholarlyArticle\\\",\\\"publicationType\\\":\\\"Journal Article\\\",\\\"inLanguage\\\":\\\"en-US\\\",\\\"headline\\\":\\\"Molecular mechanisms of T cell co-stimulation and co-inhibition.\\\",\\\"url\\\":\\\"https://www.ncbi.nlm.nih.gov/pubmed/23470321\\\",\\\"author\\\":[{\\\"@type\\\":\\\"Person\\\",\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},\\\"name\\\":\\\"Lieping Chen\\\",\\\"description\\\":\\\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\\\",\\\"url\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"email\\\":\\\"lieping.chen@yale.edu\\\",\\\"telephone\\\":\\\"+12037371819\\\",\\\"honorificSuffix\\\":[null,\\\"MD\\\",\\\"PhD\\\"],\\\"award\\\":[\\\"Elected Academician 2018\\\",\\\"Kurt Hellman Award 2018\\\",\\\"Giants of Cancer Care 2018\\\",\\\"Warren Alpert Foundation Prize 2017\\\",\\\"AAI-Steinman Award 2016\\\",\\\"William B. Coley Award 2014\\\"],\\\"jobTitle\\\":[\\\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\\\",\\\"Co-Leader, Cancer Immunology, Yale Cancer Center\\\"],\\\"affiliation\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Cancer Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Chen Lab\\\",\\\"url\\\":\\\"https://medicine.yale.edu/lab/chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Human and Translational Immunology Program\\\",\\\"url\\\":\\\"https://medicine.yale.edu/immuno/programs/hti.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunobiology\\\",\\\"url\\\":\\\"http://immunobiology.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunology\\\",\\\"url\\\":\\\"http://bbs.yale.edu/immunology\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Internal Medicine\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org/research/education/index/about/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Medical Oncology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/medonc/index.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Office of Cooperative Research\\\",\\\"url\\\":\\\"http://ocr.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatic Diseases Research Core\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatology, Allergy, & Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/raci/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"SPORE in Lung Cancer\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Cancer Center\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\\\",\\\"url\\\":\\\"http://bbs.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale University\\\",\\\"url\\\":\\\"https://www.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"alumniOf\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Drexel University, Pathology and Laboratory Medicine (1989)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Beijing Union Medical College, Beijing, China, Immunology (1986)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Fujian Medical College (1982)\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\\\",\\\"description\\\":\\\"\\\",\\\"height\\\":1200,\\\"width\\\":630,\\\"@context\\\":\\\"http://schema.org\\\"},\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"description\\\":\\\"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews. Immunology 2013, 13:227-42.\\\",\\\"@context\\\":\\\"http://schema.org\\\"}\"},{\"schemaName\":\"MedicalScholarlyArticle\",\"jsonData\":\"{\\\"@type\\\":\\\"MedicalScholarlyArticle\\\",\\\"publicationType\\\":\\\"Journal Article\\\",\\\"inLanguage\\\":\\\"en-US\\\",\\\"headline\\\":\\\"Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.\\\",\\\"url\\\":\\\"https://www.ncbi.nlm.nih.gov/pubmed/26325035\\\",\\\"author\\\":[{\\\"@type\\\":\\\"Person\\\",\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},\\\"name\\\":\\\"Lieping Chen\\\",\\\"description\\\":\\\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\\\",\\\"url\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"email\\\":\\\"lieping.chen@yale.edu\\\",\\\"telephone\\\":\\\"+12037371819\\\",\\\"honorificSuffix\\\":[null,\\\"MD\\\",\\\"PhD\\\"],\\\"award\\\":[\\\"Elected Academician 2018\\\",\\\"Kurt Hellman Award 2018\\\",\\\"Giants of Cancer Care 2018\\\",\\\"Warren Alpert Foundation Prize 2017\\\",\\\"AAI-Steinman Award 2016\\\",\\\"William B. Coley Award 2014\\\"],\\\"jobTitle\\\":[\\\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\\\",\\\"Co-Leader, Cancer Immunology, Yale Cancer Center\\\"],\\\"affiliation\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Cancer Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Chen Lab\\\",\\\"url\\\":\\\"https://medicine.yale.edu/lab/chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Human and Translational Immunology Program\\\",\\\"url\\\":\\\"https://medicine.yale.edu/immuno/programs/hti.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunobiology\\\",\\\"url\\\":\\\"http://immunobiology.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunology\\\",\\\"url\\\":\\\"http://bbs.yale.edu/immunology\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Internal Medicine\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org/research/education/index/about/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Medical Oncology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/medonc/index.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Office of Cooperative Research\\\",\\\"url\\\":\\\"http://ocr.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatic Diseases Research Core\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatology, Allergy, & Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/raci/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"SPORE in Lung Cancer\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Cancer Center\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\\\",\\\"url\\\":\\\"http://bbs.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale University\\\",\\\"url\\\":\\\"https://www.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"alumniOf\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Drexel University, Pathology and Laboratory Medicine (1989)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Beijing Union Medical College, Beijing, China, Immunology (1986)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Fujian Medical College (1982)\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\\\",\\\"description\\\":\\\"\\\",\\\"height\\\":1200,\\\"width\\\":630,\\\"@context\\\":\\\"http://schema.org\\\"},\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"description\\\":\\\"Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal Of Clinical Investigation 2015, 125:3384-91.\\\",\\\"@context\\\":\\\"http://schema.org\\\"}\"},{\"schemaName\":\"MedicalScholarlyArticle\",\"jsonData\":\"{\\\"@type\\\":\\\"MedicalScholarlyArticle\\\",\\\"publicationType\\\":\\\"Journal Article\\\",\\\"inLanguage\\\":\\\"en-US\\\",\\\"headline\\\":\\\"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.\\\",\\\"url\\\":\\\"https://www.ncbi.nlm.nih.gov/pubmed/30290139\\\",\\\"author\\\":[{\\\"@type\\\":\\\"Person\\\",\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},\\\"name\\\":\\\"Lieping Chen\\\",\\\"description\\\":\\\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\\\",\\\"url\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"email\\\":\\\"lieping.chen@yale.edu\\\",\\\"telephone\\\":\\\"+12037371819\\\",\\\"honorificSuffix\\\":[null,\\\"MD\\\",\\\"PhD\\\"],\\\"award\\\":[\\\"Elected Academician 2018\\\",\\\"Kurt Hellman Award 2018\\\",\\\"Giants of Cancer Care 2018\\\",\\\"Warren Alpert Foundation Prize 2017\\\",\\\"AAI-Steinman Award 2016\\\",\\\"William B. Coley Award 2014\\\"],\\\"jobTitle\\\":[\\\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\\\",\\\"Co-Leader, Cancer Immunology, Yale Cancer Center\\\"],\\\"affiliation\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Cancer Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Chen Lab\\\",\\\"url\\\":\\\"https://medicine.yale.edu/lab/chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Human and Translational Immunology Program\\\",\\\"url\\\":\\\"https://medicine.yale.edu/immuno/programs/hti.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunobiology\\\",\\\"url\\\":\\\"http://immunobiology.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunology\\\",\\\"url\\\":\\\"http://bbs.yale.edu/immunology\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Internal Medicine\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org/research/education/index/about/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Medical Oncology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/medonc/index.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Office of Cooperative Research\\\",\\\"url\\\":\\\"http://ocr.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatic Diseases Research Core\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatology, Allergy, & Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/raci/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"SPORE in Lung Cancer\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Cancer Center\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\\\",\\\"url\\\":\\\"http://bbs.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale University\\\",\\\"url\\\":\\\"https://www.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"alumniOf\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Drexel University, Pathology and Laboratory Medicine (1989)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Beijing Union Medical College, Beijing, China, Immunology (1986)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Fujian Medical College (1982)\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\\\",\\\"description\\\":\\\"\\\",\\\"height\\\":1200,\\\"width\\\":630,\\\"@context\\\":\\\"http://schema.org\\\"},\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"description\\\":\\\"Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 2018, 175:313-326.\\\",\\\"@context\\\":\\\"http://schema.org\\\"}\"}],\"sdlPageMetaData\":{\"tcmId\":\"tcm:25-363053-64\",\"lastPublishedDate\":\"2020-07-09T06:35:42.7059182-04:00\",\"revisionDate\":\"2019-07-15T08:40:02\",\"version\":1},\"authenticationData\":{\"isUserAuthenticated\":false,\"userName\":null},\"publicationUrl\":\"/ysm\",\"topBanner\":null,\"mainComponents\":[{\"key\":\"ProfileDetails\",\"orderOnPage\":0,\"model\":{\"mainInfo\":{\"fullName\":\"Lieping Chen\",\"suffixes\":{\"familySuffix\":null,\"nonFamilySuffixes\":[\"MD\",\"PhD\"]},\"titles\":[\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\",\"Co-Leader, Cancer Immunology, Yale Cancer Center\"],\"image\":{\"hiResUrl\":\"https://files-profile.medicine.yale.edu/images/fe7f2746-99dd-4ee9-8a33-969487a8e988\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\",\"altText\":\"Lieping Chen\",\"width\":1901,\"height\":2630,\"imageVariants\":[{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/d5ec7e6f-d53d-4519-9d63-89381f593178\",\"width\":1901,\"height\":1901},{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/06b1019e-a035-46f7-a54b-dd40954e3f6f\",\"width\":1901,\"height\":2376}]},\"editUrl\":\"https://prod.admin.profile.yale.edu/Profiles/72592/GeneralInfo/Edit\"},\"contacts\":{\"fullName\":\"Lieping Chen\",\"cvUrl\":null,\"generalContacts\":{\"email\":\"lieping.chen@yale.edu\",\"academicPhone\":{\"phoneNumber\":\"+12037371819\",\"extension\":null},\"officeFax\":null,\"clinicPhone\":null,\"clinicFax\":null,\"labPhone\":null},\"externalProfileLink\":null,\"locations\":{\"patientCareLocations\":[],\"officeLocations\":[{\"address\":{\"id\":348,\"officeName\":null,\"name\":null,\"addressLine1\":\"300 George Street\",\"addressLine2\":\"Ste Suite 203A, Room 2304\",\"city\":\"New Haven\",\"region\":\"CT\",\"country\":\"United States\",\"postalCode\":\"06511\"},\"url\":\"/ysm/profile/lieping_chen/?tab=location&locationId=939\",\"phones\":[{\"phoneNumber\":\"+12037376338\",\"extension\":null},{\"phoneNumber\":\"+12037372242\",\"extension\":null}]}],\"labLocations\":[{\"address\":{\"id\":348,\"officeName\":null,\"name\":null,\"addressLine1\":\"300 George Street\",\"addressLine2\":\"Ste Suite 203A, Room 2321\",\"city\":\"New Haven\",\"region\":\"CT\",\"country\":\"United States\",\"postalCode\":\"06511\"},\"url\":\"/ysm/profile/lieping_chen/?tab=location&locationId=938\",\"phones\":[{\"phoneNumber\":\"+12037371769\",\"extension\":null},{\"phoneNumber\":\"+12037372242\",\"extension\":null}]}]},\"mailingAddresses\":[],\"suffixes\":{\"familySuffix\":null,\"nonFamilySuffixes\":[\"MD\",\"PhD\"]},\"labLinks\":[{\"url\":\"https://medicine.yale.edu/lab/chen/\",\"text\":\"Chen Lab Page\"}],\"relatedLinks\":[{\"url\":\"http://www.youtube.com/watch?v=RsfkIK2Ae4w\",\"text\":\"\\\"Smart\\\" cancer drugs show promise\"},{\"url\":\"https://medicine.yale.edu/cancer/Transcript%20Cover%20-%202012Chen.pdf\",\"text\":\"Yale Cancer Center Answers: Discovering New Treatments for Cancer\"}],\"ymProfileUrl\":null},\"bioTab\":{\"biography\":\"

Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection.

In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.

In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.

Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.

\",\"photo\":{\"hiResUrl\":\"https://files-profile.medicine.yale.edu/images/fe7f2746-99dd-4ee9-8a33-969487a8e988\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\",\"altText\":\"Lieping Chen\",\"width\":1901,\"height\":2630,\"imageVariants\":[{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/d5ec7e6f-d53d-4519-9d63-89381f593178\",\"width\":1901,\"height\":1901},{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/06b1019e-a035-46f7-a54b-dd40954e3f6f\",\"width\":1901,\"height\":2376}]},\"gallery\":null,\"organizations\":[{\"id\":110443,\"name\":\"Cancer Immunology\",\"url\":\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\"},{\"id\":114280,\"name\":\"Chen Lab\",\"url\":\"https://medicine.yale.edu/lab/chen/\"},{\"id\":109441,\"name\":\"Human and Translational Immunology Program\",\"url\":\"https://medicine.yale.edu/immuno/programs/hti.aspx\"},{\"id\":108794,\"name\":\"Immunobiology\",\"url\":\"http://immunobiology.yale.edu\"},{\"id\":109534,\"name\":\"Immunology\",\"url\":\"http://bbs.yale.edu/immunology\"},{\"id\":108789,\"name\":\"Internal Medicine\",\"url\":\"https://medicine.yale.edu/intmed/\"},{\"id\":119325,\"name\":\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\",\"url\":\"https://www.yalecancercenter.org/research/education/index/about/\"},{\"id\":109162,\"name\":\"Medical Oncology\",\"url\":\"https://medicine.yale.edu/intmed/medonc/index.aspx\"},{\"id\":114820,\"name\":\"Office of Cooperative Research\",\"url\":\"http://ocr.yale.edu/\"},{\"id\":110315,\"name\":\"Rheumatic Diseases Research Core\",\"url\":null},{\"id\":118824,\"name\":\"Rheumatology, Allergy, & Immunology\",\"url\":\"https://medicine.yale.edu/intmed/raci/\"},{\"id\":115915,\"name\":\"SPORE in Lung Cancer\",\"url\":null},{\"id\":109631,\"name\":\"Yale Cancer Center\",\"url\":\"https://www.yalecancercenter.org\"},{\"id\":109532,\"name\":\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\",\"url\":\"http://bbs.yale.edu\"},{\"id\":110762,\"name\":\"Yale University\",\"url\":\"https://www.yale.edu/\"}],\"appointmentOrganizations\":[{\"id\":108794,\"name\":\"Immunobiology\",\"url\":\"http://immunobiology.yale.edu\"},{\"id\":109162,\"name\":\"Medical Oncology\",\"url\":\"https://medicine.yale.edu/intmed/medonc/index.aspx\"}],\"educations\":[{\"degree\":\"PhD\",\"institution\":\"Drexel University, Pathology and Laboratory Medicine (1989)\"},{\"degree\":\"MS\",\"institution\":\"Beijing Union Medical College, Beijing, China, Immunology (1986)\"},{\"degree\":\"MD\",\"institution\":\"Fujian Medical College (1982)\"}],\"honors\":[{\"award\":\"Elected Academician\",\"awardingOrganization\":\"Academia Sinica\",\"date\":\"2018\"},{\"award\":\"Kurt Hellman Award\",\"awardingOrganization\":\"Metastasis Research Society\",\"date\":\"2018\"},{\"award\":\"Giants of Cancer Care\",\"awardingOrganization\":\"OncLive\",\"date\":\"2018\"},{\"award\":\"Warren Alpert Foundation Prize\",\"awardingOrganization\":\"Warren Alpert Foundation/Harvard Medical School\",\"date\":\"2017\"},{\"award\":\"AAI-Steinman Award\",\"awardingOrganization\":\"American Association of Immunologists\",\"date\":\"2016\"},{\"award\":\"William B. Coley Award\",\"awardingOrganization\":\"Cancer Research Institute\",\"date\":\"2014\"}],\"services\":[],\"activities\":[]},\"researchTab\":{\"research\":{\"description\":\"

My laboratory is interested in:

Discovery and characterization of cell surface receptors/ligands that control T-cell responses to antigens
Cellular and molecular mechanisms by which tumors escape from immune attack
Developing novel treatments of human diseases based on our laboratory discoveries

\",\"summary\":\"

Modulation of T-cell immunity by cell surface costimulatory and coinhibitory molecules and translation of laboratory findings to treat human diseases

Specialized Terms: Lymphocyte activation and tolerance; costimulation and coinhibition; tumor microenvironment; cancer immunotherapy

\",\"researchInterests\":[\"Immunotherapy\",\"Inflammation\",\"Medical Oncology\",\"Neoplasms\",\"Autoimmunity\"],\"healthInterests\":[\"Cancer\",\"Immunology\"],\"researchImagesGallery\":null},\"publications\":[{\"title\":\"Molecular mechanisms of T cell co-stimulation and co-inhibition.\",\"citation\":\"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews. Immunology 2013, 13:227-42.\",\"year\":2013,\"link\":{\"url\":\"https://www.ncbi.nlm.nih.gov/pubmed/23470321\",\"text\":\"Molecular mechanisms of T cell co-stimulation and co-inhibition.\"}},{\"title\":\"Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.\",\"citation\":\"Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal Of Clinical Investigation 2015, 125:3384-91.\",\"year\":2015,\"link\":{\"url\":\"https://www.ncbi.nlm.nih.gov/pubmed/26325035\",\"text\":\"Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.\"}},{\"title\":\"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.\",\"citation\":\"Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 2018, 175:313-326.\",\"year\":2018,\"link\":{\"url\":\"https://www.ncbi.nlm.nih.gov/pubmed/30290139\",\"text\":\"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.\"}}],\"clinicalTrials\":[],\"coauthors\":[]},\"patientCareTab\":null,\"newsTab\":{\"searchUrl\":\"/ysm/search/?entityType=Article&profilePageName=lieping_chen\",\"news\":[{\"id\":\"25910\",\"bylineDate\":\"2020-07-08T04:00:00-04:00\",\"title\":\"Yale Cancer Center Awarded NIH SPORE Renewal for Lung Cancer Research\",\"summary\":\"Yale Cancer Center researchers were awarded a $11 million grant renewal from the National institutes of Health to fund the Yale Specialized Program of Research Excellence (SPORE) in Lung Cancer.\",\"thumbnail\":{\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/4dc4ff3d-dd83-4021-81a0-296af70abea7\",\"altText\":null,\"width\":1087,\"height\":605,\"imageVariants\":[{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/a5ee3486-464f-4609-b4b7-f3e2addb0d61\",\"width\":605,\"height\":605},{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/742f5bdd-5362-41bd-81a3-e83d1ca98e65\",\"width\":1087,\"height\":583}]},\"url\":\"/ysm/news-article/25910/\",\"isFeatured\":false,\"source\":null},{\"id\":\"23152\",\"bylineDate\":\"2020-03-16T04:00:00-04:00\",\"title\":\"Ancient Chinese Medicine Unlocks New Possibilities for Cancer Treatment\",\"summary\":\"In a landmark moment in cancer research, Yung-Chi Cheng and research partners are launching the first international clinical trial for a botanical drug, YIV-906. The trial involves patients with liver cancer and hepatitis B.\",\"thumbnail\":{\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/02df6e6a-a29d-4b2f-b88b-cea885fae263\",\"altText\":null,\"width\":1022,\"height\":594,\"imageVariants\":[{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/11ee84fa-711f-4d05-9029-ce77bef557cb\",\"width\":542,\"height\":542},{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/81fb7003-8079-41cc-a1cd-a11952b7d09e\",\"width\":1021,\"height\":548}]},\"url\":\"/ysm/news-article/23152/\",\"isFeatured\":false,\"source\":null},{\"id\":\"22874\",\"bylineDate\":\"2020-02-28T07:00:00-05:00\",\"title\":\"Ten Years of Leadership in Immunotherapy\",\"summary\":\"The last several years have been packed with revolutionary developments in immunotherapy, the decade’s biggest\\nbreakthrough in cancer treatment. Yale scientists have played leading roles in that story. Despite the tremendous progress, big challenges remain.\",\"thumbnail\":{\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/a05d22a5-adeb-48f6-960e-92a9b71cb85b\",\"altText\":null,\"width\":4128,\"height\":2752,\"imageVariants\":[{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/3b6d80df-c36b-4db0-a120-ba3e72dc33e2\",\"width\":4128,\"height\":2216},{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/35069b28-3734-4ff6-b3bd-2249e6e35486\",\"width\":2752,\"height\":2752}]},\"url\":\"/ysm/news-article/22874/\",\"isFeatured\":false,\"source\":null},{\"id\":\"22380\",\"bylineDate\":\"2020-01-22T19:15:44-05:00\",\"title\":\"Yale Cancer Center presents Research awards during annual Conclave\",\"summary\":\"Yale Cancer Center (YCC) held its annual Conclave and award ceremony at the New Haven Country Club on Monday, January 13.\",\"thumbnail\":{\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/d1fd09ba-dd23-4d21-86ce-a0ac715726ed\",\"altText\":null,\"width\":5009,\"height\":3344,\"imageVariants\":[{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/d97d45ee-45ed-4c69-972d-37d5b0f4061b\",\"width\":3344,\"height\":3344},{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/745cfb35-a444-4c26-818f-138d9a7fb7dd\",\"width\":5008,\"height\":2689}]},\"url\":\"/ysm/news-article/22380/\",\"isFeatured\":false,\"source\":null},{\"id\":\"22095\",\"bylineDate\":\"2019-12-11T05:00:00-05:00\",\"title\":\"Flipping the Script on Novel Cancer Therapy Leads to Insights Into Lupus\",\"summary\":\"The study results help explain the origins of lupus and suggest novel ways researchers might be able to provide much needed new therapy to treat the disease, the scientists said.\",\"thumbnail\":{\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/520df858-39e8-4d0c-9b2e-7379366aa7f5\",\"altText\":null,\"width\":1022,\"height\":594,\"imageVariants\":[{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/8c21a48f-0564-4572-91e3-8f6ab81cfe6b\",\"width\":594,\"height\":594},{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/f1e54a12-e164-478b-b8e2-a7e0ebd591ce\",\"width\":1022,\"height\":548}]},\"url\":\"/ysm/news-article/22095/\",\"isFeatured\":false,\"source\":null},{\"id\":\"21563\",\"bylineDate\":\"2019-10-16T15:00:00-04:00\",\"title\":\"Yale Center for Immuno-Oncology Dean's Symposium - October 11, 2019\",\"summary\":\"On October 11, Yale Center for Immuno-Oncology hosted its second annual Dean's Symposium at Harkness Auditorium at the Yale School of Medicine.\",\"thumbnail\":{\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/d1c7b2ca-fc2b-44b0-bf3a-bb7c6afa5889\",\"altText\":null,\"width\":1801,\"height\":1373,\"imageVariants\":[{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/faaaf0e2-e709-4ad2-a88a-414deb65af40\",\"width\":1373,\"height\":1373},{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/189ecd4a-fc16-496f-b5ca-2e2ef5dc7d8f\",\"width\":1801,\"height\":1235}]},\"url\":\"/ysm/news-article/21563/\",\"isFeatured\":false,\"source\":null},{\"id\":\"21407\",\"bylineDate\":\"2019-10-01T04:00:00-04:00\",\"title\":\"Yale Center for Immuno-Oncology Symposium on Friday, Oct. 11\",\"summary\":\"An all-day symposium will present the latest advances in Immuno-oncology.\",\"thumbnail\":null,\"url\":\"/ysm/news-article/21407/\",\"isFeatured\":false,\"source\":null},{\"id\":\"19363\",\"bylineDate\":\"2019-01-09T05:00:00-05:00\",\"title\":\"Another Transformational Breakthrough?\",\"summary\":\"Lieping Chen, MD, PhD, believes he has found another transformational key to treating cancer.\",\"thumbnail\":{\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/98591c98-1e8d-4d57-90cc-63028e43df51\",\"altText\":null,\"width\":1600,\"height\":1068,\"imageVariants\":[{\"dimension\":\"Square\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/a83e18b3-d29c-4b83-a9b9-7b1fa9864e7f\",\"width\":1068,\"height\":1068},{\"dimension\":\"Rectangle\",\"url\":\"https://ysm-res.cloudinary.com/image/upload/v1/yms/prod/de45b85f-84d1-4602-a954-cf83b3767fd9\",\"width\":1556,\"height\":1068}]},\"url\":\"/ysm/news-article/19363/\",\"isFeatured\":false,\"source\":null}]},\"locationsTab\":{\"addresses\":[{\"id\":938,\"address\":{\"id\":348,\"officeName\":null,\"name\":null,\"addressLine1\":\"300 George Street\",\"addressLine2\":\"Ste Suite 203A, Room 2321\",\"city\":\"New Haven\",\"region\":\"CT\",\"country\":\"United States\",\"postalCode\":\"06511\"},\"geoPoint\":{\"latitude\":41.304974,\"longitude\":-72.931337},\"phones\":[{\"phoneNumber\":\"+12037371769\",\"extension\":null},{\"phoneNumber\":\"+12037372242\",\"extension\":null}],\"activeHours\":null,\"website\":null},{\"id\":939,\"address\":{\"id\":348,\"officeName\":null,\"name\":null,\"addressLine1\":\"300 George Street\",\"addressLine2\":\"Ste Suite 203A, Room 2304\",\"city\":\"New Haven\",\"region\":\"CT\",\"country\":\"United States\",\"postalCode\":\"06511\"},\"geoPoint\":{\"latitude\":41.304974,\"longitude\":-72.931337},\"phones\":[{\"phoneNumber\":\"+12037376338\",\"extension\":null},{\"phoneNumber\":\"+12037372242\",\"extension\":null}],\"activeHours\":null,\"website\":null}]},\"metaData\":{\"title\":\"Lieping Chen, MD, PhD\",\"description\":\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\",\"imageMetaData\":{\"alt\":\"\",\"width\":1200,\"height\":630,\"url\":\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\",\"secureUrl\":\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\"},\"videoMetaData\":null,\"audioMetaData\":null,\"author\":null,\"pageType\":null,\"publishDate\":null,\"canonicalUrl\":\"/ysm/profile/lieping_chen/\"},\"structuredData\":[{\"schemaName\":\"Person\",\"jsonData\":\"{\\\"@type\\\":\\\"Person\\\",\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},\\\"name\\\":\\\"Lieping Chen\\\",\\\"description\\\":\\\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\\\",\\\"url\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"email\\\":\\\"lieping.chen@yale.edu\\\",\\\"telephone\\\":\\\"+12037371819\\\",\\\"honorificSuffix\\\":[null,\\\"MD\\\",\\\"PhD\\\"],\\\"award\\\":[\\\"Elected Academician 2018\\\",\\\"Kurt Hellman Award 2018\\\",\\\"Giants of Cancer Care 2018\\\",\\\"Warren Alpert Foundation Prize 2017\\\",\\\"AAI-Steinman Award 2016\\\",\\\"William B. Coley Award 2014\\\"],\\\"jobTitle\\\":[\\\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\\\",\\\"Co-Leader, Cancer Immunology, Yale Cancer Center\\\"],\\\"affiliation\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Cancer Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Chen Lab\\\",\\\"url\\\":\\\"https://medicine.yale.edu/lab/chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Human and Translational Immunology Program\\\",\\\"url\\\":\\\"https://medicine.yale.edu/immuno/programs/hti.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunobiology\\\",\\\"url\\\":\\\"http://immunobiology.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunology\\\",\\\"url\\\":\\\"http://bbs.yale.edu/immunology\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Internal Medicine\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org/research/education/index/about/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Medical Oncology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/medonc/index.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Office of Cooperative Research\\\",\\\"url\\\":\\\"http://ocr.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatic Diseases Research Core\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatology, Allergy, & Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/raci/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"SPORE in Lung Cancer\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Cancer Center\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\\\",\\\"url\\\":\\\"http://bbs.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale University\\\",\\\"url\\\":\\\"https://www.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"alumniOf\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Drexel University, Pathology and Laboratory Medicine (1989)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Beijing Union Medical College, Beijing, China, Immunology (1986)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Fujian Medical College (1982)\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\\\",\\\"description\\\":\\\"\\\",\\\"height\\\":1200,\\\"width\\\":630,\\\"@context\\\":\\\"http://schema.org\\\"},\\\"@context\\\":\\\"http://schema.org\\\"}\"},{\"schemaName\":\"MedicalScholarlyArticle\",\"jsonData\":\"{\\\"@type\\\":\\\"MedicalScholarlyArticle\\\",\\\"publicationType\\\":\\\"Journal Article\\\",\\\"inLanguage\\\":\\\"en-US\\\",\\\"headline\\\":\\\"Molecular mechanisms of T cell co-stimulation and co-inhibition.\\\",\\\"url\\\":\\\"https://www.ncbi.nlm.nih.gov/pubmed/23470321\\\",\\\"author\\\":[{\\\"@type\\\":\\\"Person\\\",\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},\\\"name\\\":\\\"Lieping Chen\\\",\\\"description\\\":\\\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\\\",\\\"url\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"email\\\":\\\"lieping.chen@yale.edu\\\",\\\"telephone\\\":\\\"+12037371819\\\",\\\"honorificSuffix\\\":[null,\\\"MD\\\",\\\"PhD\\\"],\\\"award\\\":[\\\"Elected Academician 2018\\\",\\\"Kurt Hellman Award 2018\\\",\\\"Giants of Cancer Care 2018\\\",\\\"Warren Alpert Foundation Prize 2017\\\",\\\"AAI-Steinman Award 2016\\\",\\\"William B. Coley Award 2014\\\"],\\\"jobTitle\\\":[\\\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\\\",\\\"Co-Leader, Cancer Immunology, Yale Cancer Center\\\"],\\\"affiliation\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Cancer Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Chen Lab\\\",\\\"url\\\":\\\"https://medicine.yale.edu/lab/chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Human and Translational Immunology Program\\\",\\\"url\\\":\\\"https://medicine.yale.edu/immuno/programs/hti.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunobiology\\\",\\\"url\\\":\\\"http://immunobiology.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunology\\\",\\\"url\\\":\\\"http://bbs.yale.edu/immunology\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Internal Medicine\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org/research/education/index/about/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Medical Oncology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/medonc/index.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Office of Cooperative Research\\\",\\\"url\\\":\\\"http://ocr.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatic Diseases Research Core\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatology, Allergy, & Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/raci/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"SPORE in Lung Cancer\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Cancer Center\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\\\",\\\"url\\\":\\\"http://bbs.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale University\\\",\\\"url\\\":\\\"https://www.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"alumniOf\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Drexel University, Pathology and Laboratory Medicine (1989)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Beijing Union Medical College, Beijing, China, Immunology (1986)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Fujian Medical College (1982)\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\\\",\\\"description\\\":\\\"\\\",\\\"height\\\":1200,\\\"width\\\":630,\\\"@context\\\":\\\"http://schema.org\\\"},\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"description\\\":\\\"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews. Immunology 2013, 13:227-42.\\\",\\\"@context\\\":\\\"http://schema.org\\\"}\"},{\"schemaName\":\"MedicalScholarlyArticle\",\"jsonData\":\"{\\\"@type\\\":\\\"MedicalScholarlyArticle\\\",\\\"publicationType\\\":\\\"Journal Article\\\",\\\"inLanguage\\\":\\\"en-US\\\",\\\"headline\\\":\\\"Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.\\\",\\\"url\\\":\\\"https://www.ncbi.nlm.nih.gov/pubmed/26325035\\\",\\\"author\\\":[{\\\"@type\\\":\\\"Person\\\",\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},\\\"name\\\":\\\"Lieping Chen\\\",\\\"description\\\":\\\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\\\",\\\"url\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"email\\\":\\\"lieping.chen@yale.edu\\\",\\\"telephone\\\":\\\"+12037371819\\\",\\\"honorificSuffix\\\":[null,\\\"MD\\\",\\\"PhD\\\"],\\\"award\\\":[\\\"Elected Academician 2018\\\",\\\"Kurt Hellman Award 2018\\\",\\\"Giants of Cancer Care 2018\\\",\\\"Warren Alpert Foundation Prize 2017\\\",\\\"AAI-Steinman Award 2016\\\",\\\"William B. Coley Award 2014\\\"],\\\"jobTitle\\\":[\\\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\\\",\\\"Co-Leader, Cancer Immunology, Yale Cancer Center\\\"],\\\"affiliation\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Cancer Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Chen Lab\\\",\\\"url\\\":\\\"https://medicine.yale.edu/lab/chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Human and Translational Immunology Program\\\",\\\"url\\\":\\\"https://medicine.yale.edu/immuno/programs/hti.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunobiology\\\",\\\"url\\\":\\\"http://immunobiology.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunology\\\",\\\"url\\\":\\\"http://bbs.yale.edu/immunology\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Internal Medicine\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org/research/education/index/about/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Medical Oncology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/medonc/index.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Office of Cooperative Research\\\",\\\"url\\\":\\\"http://ocr.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatic Diseases Research Core\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatology, Allergy, & Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/raci/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"SPORE in Lung Cancer\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Cancer Center\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\\\",\\\"url\\\":\\\"http://bbs.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale University\\\",\\\"url\\\":\\\"https://www.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"alumniOf\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Drexel University, Pathology and Laboratory Medicine (1989)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Beijing Union Medical College, Beijing, China, Immunology (1986)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Fujian Medical College (1982)\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\\\",\\\"description\\\":\\\"\\\",\\\"height\\\":1200,\\\"width\\\":630,\\\"@context\\\":\\\"http://schema.org\\\"},\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"description\\\":\\\"Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal Of Clinical Investigation 2015, 125:3384-91.\\\",\\\"@context\\\":\\\"http://schema.org\\\"}\"},{\"schemaName\":\"MedicalScholarlyArticle\",\"jsonData\":\"{\\\"@type\\\":\\\"MedicalScholarlyArticle\\\",\\\"publicationType\\\":\\\"Journal Article\\\",\\\"inLanguage\\\":\\\"en-US\\\",\\\"headline\\\":\\\"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.\\\",\\\"url\\\":\\\"https://www.ncbi.nlm.nih.gov/pubmed/30290139\\\",\\\"author\\\":[{\\\"@type\\\":\\\"Person\\\",\\\"mainEntityOfPage\\\":{\\\"@type\\\":\\\"WebPage\\\",\\\"@id\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},\\\"name\\\":\\\"Lieping Chen\\\",\\\"description\\\":\\\"Lieping Chen studies immune cell communications via cell surface protein-protein interactions. He is also interested in translating laboratory findings to treat human diseases including cancer, autoimmune diseases and infection. In 1992, Dr. Chen showed the first proof-of-concept study that the B7-CD28 family molecules could be the targets for cancer immunotherapy. This study inspires subsequent studies targeting the B7-CD28 family molecules for the treatment of human cancer.In 1999, Dr. Chen, then at the Mayo Clinic, first to discover a molecule he called B7-H1, which is now also known as PD-L1. He subsequently showed that PD-L1 is expressed by several types of tumors and that its activity can cause the death of T cells, thus preventing them from eliminating cancer cells. Bringing these lines of inquiry full circle, he later showed that blocking this interaction between PD-1 and PD-L1 by monoclonal antibodies improved the immune system’s ability to eliminate tumors in a 2002 paper. Chen’s work provided an important foundation for the subsequent development of immunotherapies designed to block this activity, and thereby enable more effective immune responses against cancer. Dr. Chen also initiated and help organized the first-in-man clinical trial of anti-PD-1 monoclonal antibody for treating human cancer in 2006, when he moved to the Johns Hopkins Medical Institute, and developed PD-L1 staining as a biomarker to predict treatment outcome. His discoveries directly led to the development of anti-PD-1/PD-L1 antibody therapy against broad spectrum of human cancers. These discoveries have revolutionized cancer treatment.Other important breakthroughs made by Dr. Chen's laboratory include the development of an agonist antibody against the 4-1BB co-stimulatory pathway, also known as CD137. Multiple 4-1BB-targeting antibodies have since been developed and are now being evaluated in clinical trials for a variety of cancer types. Dr. Chen’s laboratory also discovered various molecular pathways with T cell costimulatory and coinhibitory functions and/or their applications in human disease treatment. These pathways include B7-H2 (ICOSL), B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), TNFRSF19, RELT, LIGHT/HVEM, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15 etc. Many of these findings are now being developed clinically for the treatment of human diseases.\\\",\\\"url\\\":\\\"https://medicine.yale.edu/ysm/profile/lieping_chen/\\\",\\\"email\\\":\\\"lieping.chen@yale.edu\\\",\\\"telephone\\\":\\\"+12037371819\\\",\\\"honorificSuffix\\\":[null,\\\"MD\\\",\\\"PhD\\\"],\\\"award\\\":[\\\"Elected Academician 2018\\\",\\\"Kurt Hellman Award 2018\\\",\\\"Giants of Cancer Care 2018\\\",\\\"Warren Alpert Foundation Prize 2017\\\",\\\"AAI-Steinman Award 2016\\\",\\\"William B. Coley Award 2014\\\"],\\\"jobTitle\\\":[\\\"United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)\\\",\\\"Co-Leader, Cancer Immunology, Yale Cancer Center\\\"],\\\"affiliation\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Cancer Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/cancer/research/people/immunology.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Chen Lab\\\",\\\"url\\\":\\\"https://medicine.yale.edu/lab/chen/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Human and Translational Immunology Program\\\",\\\"url\\\":\\\"https://medicine.yale.edu/immuno/programs/hti.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunobiology\\\",\\\"url\\\":\\\"http://immunobiology.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Immunology\\\",\\\"url\\\":\\\"http://bbs.yale.edu/immunology\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Internal Medicine\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"K12 Calabresi Immuno-Oncology Training Program (IOTP)\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org/research/education/index/about/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Medical Oncology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/medonc/index.aspx\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Office of Cooperative Research\\\",\\\"url\\\":\\\"http://ocr.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatic Diseases Research Core\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Rheumatology, Allergy, & Immunology\\\",\\\"url\\\":\\\"https://medicine.yale.edu/intmed/raci/\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"SPORE in Lung Cancer\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Cancer Center\\\",\\\"url\\\":\\\"https://www.yalecancercenter.org\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale Combined Program in the Biological and Biomedical Sciences (BBS)\\\",\\\"url\\\":\\\"http://bbs.yale.edu\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Yale University\\\",\\\"url\\\":\\\"https://www.yale.edu/\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"alumniOf\\\":[{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Drexel University, Pathology and Laboratory Medicine (1989)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Beijing Union Medical College, Beijing, China, Immunology (1986)\\\",\\\"@context\\\":\\\"http://schema.org\\\"},{\\\"@type\\\":\\\"Organization\\\",\\\"name\\\":\\\"Fujian Medical College (1982)\\\",\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"image\\\":{\\\"@type\\\":\\\"ImageObject\\\",\\\"url\\\":\\\"https://ysm-res.cloudinary.com/image/upload/c_limit,f_auto,h_630,q_auto,w_1200/v1/yms/prod/fe7f2746-99dd-4ee9-8a33-969487a8e988\\\",\\\"description\\\":\\\"\\\",\\\"height\\\":1200,\\\"width\\\":630,\\\"@context\\\":\\\"http://schema.org\\\"},\\\"@context\\\":\\\"http://schema.org\\\"}],\\\"description\\\":\\\"Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 2018, 175:313-326.\\\",\\\"@context\\\":\\\"http://schema.org\\\"}\"}],\"isResearchProfile\":false}}],\"sidebarComponents\":[]}"

Contact Information

Lab Location

Office Location

Related Links

Biography

Research & Publications

News

Locations

Locations